Ser103

Site Information
AMBIGUOUS SITES: ognl.NoConversionPossible:
NEKEtMQsLNDRLAG SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 34499807
Available spectra: 2 CST

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 )
Disease tissue studied:	gastric cancer ( 7 ) , lung cancer ( 3 , 4 , 5 ) , non-small cell lung cancer ( 4 , 5 , 6 , 8 ) , non-small cell lung adenocarcinoma ( 3 , 4 , 5 ) , non-small cell squamous cell lung carcinoma ( 3 )
Relevant cell line - cell type - tissue:	A549 (pulmonary) ( 6 ) , Cal-12T (pulmonary) ( 5 ) , DMS153 (pulmonary) ( 4 ) , HCC15 (pulmonary) ( 3 ) , HCC44 (pulmonary) ( 5 ) , liver ( 2 ) , LOU-NH91 (squamous) ( 3 ) , lung ( 3 , 4 , 5 ) , MKN-45 (gastric) ( 7 ) , NCI-H1437 (pulmonary) ( 4 , 5 ) , NCI-H1666 (pulmonary) ( 5 ) , NCI-H1703 (squamous) ( 3 ) , NCI-H2073 (pulmonary) ( 3 , 4 ) , NCI-H209 (pulmonary) ( 4 ) , NCI-H2342 (pulmonary) ( 3 ) , NCI-H2405 (pulmonary) ( 5 ) , NCI-H3255 (pulmonary) ( 8 ) , NCI-H838 (pulmonary) ( 4 )

References
1	Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704 24719451 Curated Info
2	Bian Y, et al. (2014) An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome. J Proteomics 96, 253-62 24275569 Curated Info
3	Rikova K, Hall B (2013) CST Curation Set: 20739, 21166, 30167, 30168, 30169; Year: 2013; Biosample/Treatment: cell line, H2342, H2073, Lou-NH91, HCC15, H1703; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
4	Rikova K, Hall B (2013) CST Curation Set: 20742, 21169, 30176, 30177, 30178; Year: 2013; Biosample/Treatment: cell line, H838, DMS153, H2073, H209, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
5	Rikova K, Hall B (2013) CST Curation Set: 20741, 21168, 30173, 30174, 30175; Year: 2013; Biosample/Treatment: cell line, H1666, CAL-12T, H2405, HCC44, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
6	Rikova K (2012) CST Curation Set: 16144; Year: 2012; Biosample/Treatment: cell line, A549/iressa, gleevec, crizotinib; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST] Curated Info
7	Rikova K (2012) CST Curation Set: 16141; Year: 2012; Biosample/Treatment: cell line, MKN45/crizotinib; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST](AGC) Curated Info
8	Rikova K (2012) CST Curation Set: 16142; Year: 2012; Biosample/Treatment: cell line, H3255/iressa; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST](AGC) Curated Info
9	Rikova K (2012) CST Curation Set: 13916; Year: 2012; Biosample/Treatment: cell line, Mix of TMT treated cell lines 2/treated; Disease: -; SILAC: -; Curated Info
10	Rikova K (2011) CST Curation Set: 13123; Year: 2011; Biosample/Treatment: cell line, MGH-1/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
11	Rikova K (2011) CST Curation Set: 13124; Year: 2011; Biosample/Treatment: cell line, MGH-2/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info